CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2019-- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives will participate in the following investor conferences:

• Piper Jaffray 31^st Annual Healthcare Conference on Tuesday, December 3, 2019, at 8:30 a.m. ET in New York City, New York.
• Evercore ISI 2^nd Annual HealthCONx Conference on Wednesday, December 4, 2019, at 3:50 p.m. ET in Boston, Massachusetts.

Where applicable, a live webcast and replay of Akebia’s presentation will be available on the Company’s website at www.akebia.com.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005190/en/

Source: Akebia Therapeutics, Inc.

Kristen K. Sheppard, Esq.
ir@akebia.com